These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 26717390)

  • 1. Nafamostat Mesilate as an Anticoagulant During Continuous Renal Replacement Therapy in Patients With High Bleeding Risk: A Randomized Clinical Trial.
    Choi JY; Kang YJ; Jang HM; Jung HY; Cho JH; Park SH; Kim YL; Kim CD
    Medicine (Baltimore); 2015 Dec; 94(52):e2392. PubMed ID: 26717390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nafamostat mesilate as an anticoagulant during continuous veno-venous hemodialysis: a three-year retrospective cohort study.
    Maruyama Y; Yoshida H; Uchino S; Yokoyama K; Yamamoto H; Takinami M; Hosoya T
    Int J Artif Organs; 2011 Jul; 34(7):571-6. PubMed ID: 21786254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ability of nafamostat mesilate to prolong filter patency during continuous renal replacement therapy in patients at high risk of bleeding: a randomized controlled study.
    Lee YK; Lee HW; Choi KH; Kim BS
    PLoS One; 2014; 9(10):e108737. PubMed ID: 25302581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nafamostat mesilate for anticoagulation in continuous renal replacement therapy.
    Hwang SD; Hyun YK; Moon SJ; Lee SC; Yoon SY
    Int J Artif Organs; 2013 Mar; 36(3):208-16. PubMed ID: 23404639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of nafamostat mesilate and unfractionated heparin as anticoagulants during continuous renal replacement therapy.
    Makino S; Egi M; Kita H; Miyatake Y; Kubota K; Mizobuchi S
    Int J Artif Organs; 2016 Jan; 39(1):16-21. PubMed ID: 26868216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of nafamostat mesylate in continuous renal replacement therapy among patients at high risk of bleeding.
    Baek NN; Jang HR; Huh W; Kim YG; Kim DJ; Oh HY; Lee JE
    Ren Fail; 2012; 34(3):279-85. PubMed ID: 22251267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between Intra-Circuit Activated Clotting Time and Incidence of Bleeding Complications during Continuous Renal Replacement Therapy using Nafamostat Mesilate: a Retrospective Pilot Observational Study.
    Miyatake Y; Makino S; Kubota K; Egi M; Mizobuchi S
    Kobe J Med Sci; 2017 Aug; 63(1):E30-E36. PubMed ID: 29434171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nafamostat mesylate versus regional citrate anticoagulation for continuous renal replacement therapy in patients at high risk of bleeding: a retrospective single-center study.
    Liu D; Zhao J; Xia H; Dong S; Yan S; Zhuang Y; Chen Y; Peng H
    Eur J Med Res; 2024 Jan; 29(1):72. PubMed ID: 38245802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of nafamostat mesilate to citrate anticoagulation in pediatric continuous kidney replacement therapy.
    Miyaji MJ; Ide K; Takashima K; Maeno M; Krallman KA; Lazear D; Goldstein SL
    Pediatr Nephrol; 2022 Nov; 37(11):2733-2742. PubMed ID: 35348901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose of nafamostat mesylate during continuous kidney replacement therapy in critically ill patients: a two-centre observational study.
    Kameda S; Maeda A; Maeda S; Inoue Y; Takahashi K; Kageyama A; Doi K; Fujii T
    BMC Nephrol; 2024 Feb; 25(1):69. PubMed ID: 38408970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of nafamostat mesilate anticoagulation in blood purification treatment of critically ill patients: a systematic review and meta-analysis.
    Lin Y; Shao Y; Liu Y; Yang R; Liao S; Yang S; Xu M; He J
    Ren Fail; 2022 Dec; 44(1):1263-1279. PubMed ID: 35930302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous renal replacement therapy without anticoagulation in critically ill patients at high risk of bleeding: A systematic review and meta-analysis.
    Zhang W; Bai M; Yu Y; Chen X; Zhao L; Chen X
    Semin Dial; 2021 May; 34(3):196-208. PubMed ID: 33400846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Safety and efficacy of regional citrate anticoagulation in continuous renal replacement therapy in the presence of acute kidney injury after hepatectomy].
    Zhang C; Lin T; Zhang J; Liang H; Di Y; Li N; Gao J; Wang W; Liu S; Wang Z; Jiang H; Liu C
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2018 Aug; 30(8):777-782. PubMed ID: 30220281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Filter Lifespan, Treatment Effect, and Influencing Factors of Continuous Renal Replacement Therapy for Severe Burn Patients.
    Yue Q; Wu H; Xi M; Li F; Li T; Li Y
    J Burn Care Res; 2024 May; 45(3):764-770. PubMed ID: 38113522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nafamostat mesilate is not appropriate as an anticoagulant during continuous renal replacement therapy in dogs.
    Shimokawa Miyama T; Yoshioka C; Minami K; Okawa T; Hiraoka H; Itamoto K; Mizuno T; Okuda M
    J Vet Med Sci; 2010 Mar; 72(3):363-7. PubMed ID: 19959883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cov-hep study: heparin in standard anticoagulation based on citrate for continuous veno-venous hemodialysis in patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.
    Lins PRG; de Albuquerque CCC; Assis CF; Rodrigues BCD; E Siqueira Campos BP; de Oliveira Valle E; Cabrera CPS; de Oliveira Gois J; Segura GC; Strufaldi FL; Mainardes LC; Ribeiro RG; Via Reque Cortes DDP; Lutf LG; de Oliveira MFA; Sales GTM; Smolentzov I; Reichert BV; Andrade L; Seabra VF; Rodrigues CE
    Trials; 2020 Nov; 21(1):920. PubMed ID: 33176886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How do filter types of renal replacement therapy affect survival in critically ill patients? Concerns about adsorption of nafamostat mesylate on AN69 membranes.
    Qian Y; Wu W; Wang M; Wei Y; Zhong M
    BMC Nephrol; 2024 Sep; 25(1):314. PubMed ID: 39304801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
    Tsujimoto H; Tsujimoto Y; Nakata Y; Fujii T; Takahashi S; Akazawa M; Kataoka Y
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD012467. PubMed ID: 33314078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticoagulation in acute blood purification for acute renal failure in critical care.
    Shinoda T
    Contrib Nephrol; 2010; 166():119-125. PubMed ID: 20472999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Regional Citrate Anticoagulation vs Systemic Heparin Anticoagulation During Continuous Kidney Replacement Therapy on Dialysis Filter Life Span and Mortality Among Critically Ill Patients With Acute Kidney Injury: A Randomized Clinical Trial.
    Zarbock A; Küllmar M; Kindgen-Milles D; Wempe C; Gerss J; Brandenburger T; Dimski T; Tyczynski B; Jahn M; Mülling N; Mehrländer M; Rosenberger P; Marx G; Simon TP; Jaschinski U; Deetjen P; Putensen C; Schewe JC; Kluge S; Jarczak D; Slowinski T; Bodenstein M; Meybohm P; Wirtz S; Moerer O; Kortgen A; Simon P; Bagshaw SM; Kellum JA; Meersch M;
    JAMA; 2020 Oct; 324(16):1629-1639. PubMed ID: 33095849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.